Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...288289290291292293294295296297298...10661067»
  • ||||||||||  cyclosporine / Generic mfg.
    Journal:  TAFRO syndrome with renal biopsy successfully treated with steroids and cyclosporine: a case report. (Pubmed Central) -  Jul 27, 2022   
    The method was found to be sensitive, precise and accurate in human plasma and bovine aqueous humor and can be applied for the quantification of these compounds in plasma, aqueous humor and pharmaceuticals. Given that only few reports of improvement in the systemic symptoms of TAFRO syndrome using steroids and cyclosporine exist, our study investigating the relationship between the pathogenesis of TAFRO syndrome and renal disorders, as well as treatment methods, provides valuable insights.
  • ||||||||||  Chirocaine (levobupivacaine) / Purdue, AbbVie
    Journal:  Lower-Leg Amputation Performed Under Regional Anesthesia in a Patient with Epidermolysis Bullosa: A Case Report. (Pubmed Central) -  Jul 27, 2022   
    The patient was discharged 12 days postoperatively without additional signs of infection or new blister formation, although surgical wound healing was delayed. CONCLUSIONS For patients with EB who have had repeated blistering and scarring, even from a minor external force, attention should be paid to airway management and avoidance of additional skin damage caused by external forces.
  • ||||||||||  dexamethasone / Generic mfg.
    Enrollment open, Surgery:  MIDCAB (Mid-Calf Block) for Foot Surgery (clinicaltrials.gov) -  Jul 27, 2022   
    P4,  N=20, Recruiting, 
    Trial completion date: Apr 2022 --> Sep 2022 Not yet recruiting --> Recruiting
  • ||||||||||  dexamethasone injection / Generic mfg.
    Journal:  HSPA5 Inhibitor Meliorate DSS-Induced Colitis through HSPA1A/CHIP. (Pubmed Central) -  Jul 27, 2022   
    Thirty-two C57BL/6 mice were randomly divided into four groups (8 mice per group): normal control group, DSS model group, HSPA5 inhibitor (HA15) group (intraperitoneal injection), and dexamethasone (DXM) group (intraperitoneal injection)...HA15 can improve the differentiation and function of Treg cells by inhibiting the HSPA1A/CHIP pathway, thereby improving ulcerative colitis. Therefore, inhibiting the expression of HSPA5 may serve as a new approach to treat ulcerative colitis.
  • ||||||||||  bortezomib / Generic mfg., dexamethasone / Generic mfg.
    Journal:  The Concilium of Information Processing Networks of Chemical Oscillators for Determining Drug Response in Patients With Multiple Myeloma. (Pubmed Central) -  Jul 27, 2022   
    The single-gene networks optimized on a training set containing outcomes of 239 therapies, 169 using bortezomib and 70 using dexamethasone, show up to 71% accuracy in differentiating between non-responsive and responsive patients. If the results of single-gene networks are combined into the concilium with the majority voting strategy, then the accuracy of predicting the patient's response to the therapy increases to ∼ 85%.
  • ||||||||||  dexamethasone / Generic mfg., bleomycin / Generic mfg.
    Journal:  Targeting Multiple End Organs in Lupus and Other Systemic Rheumatic Diseases by Inhibiting Bruton's Tyrosine Kinase. (Pubmed Central) -  Jul 27, 2022   
    Here, we extend these observations to 4 additional models of end-organ inflammation: (a) BWF1 lupus nephritis mice, (b) anti-GBM nephritis, (c) bleomycin-induced systemic sclerosis like skin disease, and (d) bleomycin-induced lung disease...Both low-dose and high-dose BTKB66 profoundly blocked renal disease in the anti-GBM nephritis model, with efficacy that was comparable to that seen with dexamethasone...Therapeutic benefit was associated with lower numbers of macrophages, proliferating macrophages and activated T-cells in the respective injured organs. The observation that these immune cells play key roles in driving end organ inflammation in multiple systemic rheumatic diseases have broad implications for the use of BTKB66 in managing patients with systemic rheumatic diseases where multiple end organs are afflicted, including lupus and systemic sclerosis.
  • ||||||||||  Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer
    Trial primary completion date:  ALL Adult Consortium Trial: Adult ALL Trial (clinicaltrials.gov) -  Jul 26, 2022   
    P2,  N=112, Active, not recruiting, 
    These hub genes are expected to be biomarkers and therapeutic targets for the diagnosis and treatment of CBS. Trial primary completion date: Jun 2022 --> Dec 2022
  • ||||||||||  Libtayo (cemiplimab-rwlc) / Regeneron
    Trial completion date, Trial primary completion date, Metastases:  CONTRAC: Cemiplimab in AlloSCT/SOT Recipients With CSCC (clinicaltrials.gov) -  Jul 26, 2022   
    P1,  N=12, Recruiting, 
    Trial primary completion date: Jun 2022 --> Dec 2022 Trial completion date: Jul 2023 --> Jan 2024 | Trial primary completion date: Jul 2022 --> Jan 2023
  • ||||||||||  Decadron (dexamethasone) / Merck (MSD)
    Trial completion date, Trial primary completion date:  Steroids and Pain Control After Tonsillectomy (clinicaltrials.gov) -  Jul 26, 2022   
    P2,  N=150, Recruiting, 
    Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Jul 2022 --> Jan 2023 Trial completion date: Jun 2022 --> Jul 2023 | Trial primary completion date: May 2022 --> Jul 2023
  • ||||||||||  Zilretta (triamcinolone acetonide ER) / Pacira
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  SLAM: Success of Long-acting Anti-inflammatories After Anterior Cruciate Ligament and Meniscal Injury (clinicaltrials.gov) -  Jul 26, 2022   
    P2,  N=6, Terminated, 
    Trial completion date: Jun 2022 --> Jul 2023 | Trial primary completion date: May 2022 --> Jul 2023 N=30 --> 6 | Trial completion date: Oct 2023 --> Jul 2022 | Recruiting --> Terminated | Trial primary completion date: Apr 2023 --> Jul 2022; Funding Termination
  • ||||||||||  hydrocortisone / Generic mfg.
    Enrollment open, Trial completion date, Trial primary completion date:  Methylene Blue as a Third-line Vasopressor in Septic Shock (clinicaltrials.gov) -  Jul 26, 2022   
    P2,  N=250, Recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Aug 2022 --> Jan 2023 | Trial primary completion date: May 2022 --> Dec 2022 Unknown status --> Recruiting | Trial completion date: Mar 2022 --> Nov 2024 | Trial primary completion date: Oct 2021 --> Oct 2024
  • ||||||||||  hydrocortisone / Generic mfg.
    Trial completion:  ReOxy Therapy in the Rehabilitation of Chronic Low Back Pain Patients With Comorbidity (clinicaltrials.gov) -  Jul 25, 2022   
    P=N/A,  N=90, Completed, 
    Unknown status --> Recruiting | Trial completion date: Mar 2022 --> Nov 2024 | Trial primary completion date: Oct 2021 --> Oct 2024 Active, not recruiting --> Completed
  • ||||||||||  Darzalex (daratumumab) / J&J
    Trial completion date:  A Study of Daratumumab (clinicaltrials.gov) -  Jul 24, 2022   
    P3b,  N=400, Not yet recruiting, 
    Suppression of GR-target genes indicated systemic GR antagonism by RELA. Trial completion date: Jan 2026 --> Apr 2026
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  A collection of inducible transcription factor-GR fusion lines for functional analyses in Arabidopsis thaliana. (Pubmed Central) -  Jul 24, 2022   
    To evaluate these transcription lines, we induced the TF-GR lines of phytochrome-interacting factor 4, which controls photomorphogenesis, with synthetic glucocorticoid dexamethasone...Among these, we found two lines showing higher anthocyanin accumulation under light conditions and we examined the regulating genes. These results indicate that the TF-GR lines can be used to dissect functionally redundant genes in plants and demonstrate that the TF-GR line collection can be used as an effective tool for functional analysis of TFs.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Conductive Microneedle Patch with Electricity-Triggered Drug Release Performance for Atopic Dermatitis Treatment. (Pubmed Central) -  Jul 24, 2022   
    For AD treatment in vivo, this MN patch with electricity-triggered drug release performance could effectively deliver more drugs into the skin compared with other controls such as dexamethasone cream, which efficiently alleviate AD. In sum, this work not only developed a smart patch for improving AD treatment but also provided a promising approach of transdermal drug delivery on demand.
  • ||||||||||  hydrocortisone / Generic mfg.
    Review, Journal:  Update on vitamin C administration in critical illness. (Pubmed Central) -  Jul 24, 2022   
    The effect of intravenous vitamin C in critically ill patients has yet to be determined and might be dose-dependent. Clinical studies of very high or mega doses of vitamin C are justified by preclinical data.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Impact of Corticosteroids on the Proportions of Circulating Tfh Cell Subsets in Patients With Systemic Lupus Erythematous. (Pubmed Central) -  Jul 24, 2022   
    To test the effects of corticosteroid on Tfh cells, PBMC harvested from both SLE and healthy controls were cocultured with dexamethasone, and then analyzed by Flow cytometry...Our study investigated the distribution of circulating Tfh subsets in lupus patients. Corticosteroids treatment not only down-regulated the proportion of circulating Tfh cells, but also altered the distribution of Tfh subsets in vivo and in vitro.
  • ||||||||||  hydrocortisone / Generic mfg.
    Journal:  Xiao-Chai-Hu Decoction Ameliorates Poly (I:C)-Induced Viral Pneumonia through Inhibiting Inflammatory Response and Modulating Serum Metabolism. (Pubmed Central) -  Jul 24, 2022   
    Serum untargeted metabolomics analysis showed that XCH treatment could affect 18 metabolites in serum such as creatine, hydroxyproline, cortisone, hydrocortisone, corticosterone, hypotaurine, and taurine...In conclusion, our study demonstrated that treatment with XCH can ameliorate viral pneumonia and reduce inflammatory response in viral pneumonia. The mechanism of action of XCH in the treatment of viral pneumonia may be associated with inhibiting the activation of PI3K/AKT/NF-κB signaling pathway in lung and regulating arginine and proline metabolism, steroid hormone biosynthesis, and taurine and hypotaurine metabolism in serum.
  • ||||||||||  etoposide IV / Generic mfg., dexamethasone injection / Generic mfg.
    Journal:  Dexamethasone as an anti-cancer or Hepatotoxic. (Pubmed Central) -  Jul 23, 2022   
    The best effect of coenzyme Q10 on dexamethasone-induced hepatotoxicity is 50 mg/kg.As a result, dexamethasone (alone and combined with etoposide) has an anti-cancer effect by damaging DNA and inducing oxidative stress. Also, CoQ10 has antioxidant effects against dexamethasone-induced hepatotoxicity by improving mitochondrial function and reducing caspase-3 activity.
  • ||||||||||  Xipere (triamcinolone acetonide) / Clearside Biomedical, Bausch Health, Arctic Vision
    Journal:  Suprachoroidal delivery enables targeting, localization and durability of small molecule suspensions. (Pubmed Central) -  Jul 23, 2022   
    Drug delivery to the suprachoroidal space (SCS®) has become a clinical reality after the 2021 FDA approval of CLS-TA, a triamcinolone acetonide injectable suspension for suprachoroidal use (XIPERE®), administered via a microneedle-based device, the SCS Microinjector®...The clinical evaluations of the safety, tolerability and efficacy of SC delivered triamcinolone further supports potential of SC small molecule suspensions as a clinically viable strategy for the treatment of chorioretinal diseases. Also highlighted are current limitations, key pharmacological considerations, and future opportunities for the SC microinjector platform as a safe, effective, and long-acting drug delivery platform for choroioretinal therapies.